Key facts
- Clairity’s last known valuation is $137.0M (Nov 2025).
- It has raised $53.8M; the latest was Later Stage VC ($50.0M) in Nov 2025.
- Notable investors include ACE GESTAO GLOBAL, Breast Cancer Research Foundation, Santé Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Clairity
- ·The full record, as it builds
Funding rounds
No funding rounds for Clairity are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Clairity
Developer of a mammography-based deep-learning platform designed for early breast cancer detection. The company's screening platform offers AI-based breast cancer risk analytics with improved accuracy and bias-free results that improve early detection and diagnosis, enabling healthcare institutions to cultivate trust, reduce the cost of care, and save lives.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2019
- Employees
- 16
- Website
- clairity.com/
- Ownership
- Privately Held (backing)
Clairity doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Clairity shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Clairity in its N-PORT filings yet. We sweep new filings monthly.